News

Pharmaceutical Technology on MSN12h
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly’s Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...
Hosted on MSN9mon
Eli Lilly's tirzepatide is off the FDA's shortage list: What it ... - MSN
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
The 3 Things That Matter for Eli Lilly Now
Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...
Fox Business1y
FDA approves Eli Lilly's tirzepatide for weight loss
Shares of Eli Lilly and Co. rose during trading Wednesday following the news. Tirzepatide was previously approved to treat Type 2 diabetes and was sold under the brand name Mounjaro.
NPR2y
Eli Lilly releases data for a new weight-loss drug to tackle ... - NPR
Eli Lilly says its working to expand its manufacturing capacity, to ramp up in anticipation of approval. As with any medication, tirzepatide has some side effects.
NBC 10 Philadelphia1y
FDA approves Eli Lilly's tirzepatide for weight loss, paving way for ...
The list price of tirzepatide for weight loss is $1,059.87 per month for six different dose sizes, which is about 20% lower than that of Wegovy, Eli Lilly said in a press release.
Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial miss
Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.